MBX Biosciences, Inc. entered into a four-year lease agreement for approximately 13,642 square feet of new office and laboratory space in Burlington, MA. The estimated lease commencement date is May 1, 2026, with rent commencing five months later, around October 1, 2026. The aggregate base rent over the four-year term is approximately $3.4 million, with annual increases of 3.0%. Richard Bartram will resign as Chief Financial Officer effective March 15, 2026, but his departure is not due to any dispute or disagreement. Mr. Bartram will receive a severance package including 12 months of base salary ($515,000), 12 months of employer-paid COBRA premiums, accelerated vesting of 82,448 stock options and 3,750 restricted stock units, and a $13,400 lump sum payment for additional COBRA coverage. He will also serve as a consultant for one month post-resignation, during which his equity awards will continue to vest. John Smither has been appointed Interim Chief Financial Officer, effective March 16, 2026. Mr. Smither, age 73, brings over 40 years of experience in biotechnology finance, including previous CFO roles at other public companies. His compensation includes an annualized base salary of $325,000, a target annual bonus of 40% of earned income (pro-rated for the first year), and a $25,000 sign-on bonus.